The Efficacy of Stem Cell Therapy in Bone Regeneration

Kamil Muslim M. Albouri[1], Ahmed Abdullah Ahmed Al-Safer[2], Adnan Ibrahim A. Alsahaf[3], Mohammed Saeed H. Al Jawad[4], Mouslm Hassan Almohammedali[5], Asrar Saleh Abbas[6], Mahdi Muslim M. Albouri[7], Ahmed Hassan Ahmed Almidani[8], Hissain Hassan Alaseel[9], Fatima Kamil M. Albouri[10]

[1] Consultant - Orthopedic Surgery - Eastern Health Cluster 1 - Qatif Central Hospital, Qatif, Eastern Province, Saudi Arabia

[2] Registrar - Orthopedic Surgery - Eastern Health Cluster 1 - Qatif Central Hospital, Qatif, Eastern Region, Saudi Arabia

[3] General Practitioner - Eastern Health Cluster 1 - Qatif Central Hospital, Qatif, Eastern Province, Saudi Arabia

[4] General Practitioner - Eastern Health Cluster 1 - Qatif Central Hospital, Qatif, Eastern Province, Saudi Arabia

[5] General Practitioner - Eastern Health Cluster 1 - Qatif Central Hospital, Qatif, Eastern Province, Saudi Arabia

[6] Nursing Technician - Eastern Health Cluster 1 - Safwa General Hospital, Qatif, Eastern Province, Saudi Arabia

[7] Dental Assistant - Health Cluster 1 - Dammam Medical Complex, Dammam, Eastern Province, Saudi Arabia

[8] Nursing Health Assistant - Eastern Health Cluster 1 - Qatif Central Hospital, Qatif, Eastern Province, Saudi Arabia

[9] Intern Doctor - Eastern Health Cluster 1 - Qatif Central Hospital, Qatif, Eastern Province, Saudi Arabia

[10] Medical Student - Riyadh Health Cluster 1 - Dar Al Uloom University, Riyadh, Saudi Arabia

***Abstract*:**

Stem cell therapy has emerged as a promising approach for enhancing bone regeneration, particularly in cases of critical-sized bone defects and other orthopedic injuries. Stem cells possess unique properties, including the ability to differentiate into various cell types, including osteoblasts, which are essential for bone formation. Research has shown that both mesenchymal stem cells (MSCs) and embryonic stem cells (ESCs) can promote bone healing by not only differentiating into osteogenic lineages but also by releasing bioactive molecules that stimulate local tissue regeneration. Various studies have demonstrated improved outcomes in bone healing and integration when stem cells are used in conjunction with biomaterials or scaffolds, creating an optimal environment for bone tissue engineering. Clinical applications of stem cell therapy have also highlighted the significant role of patient-specific factors in treatment efficacy. Individual variability, influenced by age, underlying health conditions, and the extent of bone damage, can affect the regenerative potential of stem cells. As a result, ongoing research is focused on optimizing cell sourcing, delivery methods, and the use of adjunct therapies to enhance the therapeutic effect. Early clinical trials indicate that stem cell therapy may lead to faster recovery times and improved functional outcomes compared to traditional bone repair techniques. However, further investigations are necessary to fully establish standardized protocols and assess the long-term benefits and safety of stem cell applications in bone regeneration.

***Keywords*:** Stem Cell Therapy,Bone Regeneration, Mesenchymal Stem Cells (MSCs), Osteogenesis, Tissue Engineering, Biomaterials, Clinical Applications, Regenerative Medicine, Individual Variability, Functional Outcomes

Introduction:

Bone regeneration is a pivotal field within regenerative medicine, occupying a significant niche in the treatment of skeletal defects, fractures, and degenerative diseases. Current strategies to promote bone healing frequently involve pharmacological, physical, or surgical means, yet these approaches can fall short in facilitating thorough and effective recovery. As the complexity of bone regeneration becomes increasingly understood, the integration of stem cell therapy has emerged as a promising solution. Stem cell therapy leverages the unique properties of stem cells—namely, their ability to differentiate into various cell types and their capacity to self-renew [1].

Bone is a dynamic tissue, constantly undergoing cycles of remodeling and repair. However, certain conditions—such as severe fractures, osteoarthritis, osteoporosis, and congenital defects—can severely impair the body's natural bone healing processes. In such cases, conventional treatments may not yield favorable outcomes. Traditional methods, including autografts and allografts, although effective, often come with substantial drawbacks like limited availability, donor site morbidity, and immunological responses. Stem cell therapy emerges as a revolutionary alternative, offering a less invasive solution that harnesses the body's intrinsic regenerative capabilities [2].

To grasp the potential of stem cell therapy in bone regeneration, it is essential to distinguish between the various types of stem cells employed in this therapeutic context. Key types of stem cells used include mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), and induced pluripotent stem cells (iPSCs). Among these, MSCs, which can be derived from various sources such as bone marrow, adipose tissue, and even dental pulp, have garnered particular attention. These cells possess the unique ability to differentiate into osteoblasts, the cells responsible for bone formation, and secrete bioactive factors that enhance the healing process. This interplay of differentiation and paracrine signaling creates an environment conducive to bone repair, enabling stem cells to not only replace lost cells but also to stimulate the activity of resident cells involved in bone remodeling [3].

Research has provided compelling evidence of the efficacy of stem cell therapy in preclinical and clinical settings. Numerous animal studies have demonstrated that the application of MSCs significantly improves bone healing in models of critical-sized defects, fractures, and bone-related diseases. For instance, the local delivery of MSCs in scaffolds or hydrogels has been shown to enhance osteogenesis and stimulate vascularization, vital components of successful bone repair. Transitioning these findings to clinical applications, several human clinical trials have reported promising outcomes in the use of MSCs for treating challenging bone injuries and conditions. Although results have been heterogeneous, many studies indicate a notable enhancement in bone density and structure following stem cell application [4].

Despite the optimism surrounding the use of stem cells for bone regeneration, this therapeutic approach is not without challenges. Regulatory hurdles, variability in cell sources, optimal delivery methods, and ethical considerations in the use of certain types of stem cells pose significant obstacles. Moreover, standardization of protocols and long-term safety and efficacy assessments are critical to advancing stem cell therapy from the laboratory to widespread clinical practice. There remains a pressing need for more robust, multicenter trials that adequately address these concerns and elucidate the long-term outcomes and potential complications associated with stem cell interventions in bone regeneration [5].

Looking ahead, the horizon for stem cell therapy in bone regeneration appears promising, yet the path to fully realizing its potential is fraught with complexities. Advances in biomaterials, 3D bioprinting, and gene editing technologies may pave the way for more effective and personalized stem cell therapies. Given the increasing prevalence of bone-related disorders in an aging population, further research in this area is not only warranted but necessary. Understanding the interplay between stem cells and the skeletal microenvironment, as well as optimizing therapeutic strategies, will be essential in harnessing the full potential of stem cell therapy for bone regeneration [6].

Mechanisms of Action: How Stem Cells Facilitate Bone Healing:

Bone healing, a complex biological process, is crucial for the restoration of skeletal integrity following injury or surgical intervention. This regenerative ability has long intrigued researchers, particularly in the context of stem cell therapy, which offers promising avenues for enhancing the body's natural healing mechanisms. Stem cells, characterized by their unique ability to self-renew and differentiate into various cell types, play a pivotal role in bone healing through a multitude of mechanisms [7].

Stem cells can be classified into two major categories: embryonic stem cells (ESCs) and adult stem cells, also known as somatic or tissue-specific stem cells. In the context of bone healing, adult stem cells, particularly mesenchymal stem cells (MSCs), are of particular interest. MSCs are primarily found in bone marrow, but they can also be isolated from other tissues such as adipose tissue and synovial membranes. These cells have the capacity to differentiate into various lineages, including osteoblasts (bone-forming cells), chondrocytes (cartilage-forming cells), and adipocytes (fat cells) [8].

The regenerative potential of these stem cells is harnessed in therapeutic applications aiming to promote bone healing. Bone healing is a multi-phase process involving inflammation, bone formation, and remodeling, wherein stem cells contribute substantially during these stages [9].

The initial phase of bone healing is marked by inflammation, which facilitates the recruitment of stem cells to the injury site. Following this, the cells must proliferate and differentiate to replace damaged tissue. MSCs, upon being activated, have the capacity to differentiate into osteoblasts, which are essential for new bone formation. The osteogenic differentiation of MSCs is governed by a multitude of factors, including mechanical loading, growth factors such as bone morphogenetic proteins (BMPs), and the presence of extracellular matrix components [9].

In vitro studies have demonstrated that MSCs can be induced to undergo osteoblast differentiation through biochemical cues. These include specific growth factors like BMP-2, which initiates a cascade of signaling pathways, leading to the expression of osteogenic markers, such as alkaline phosphatase and runt-related transcription factor 2 (Runx2). Once differentiated, osteoblasts secrete extracellular matrix proteins, including collagen, which serves as a scaffold for mineralization, thereby facilitating the repair of the fractured bone [10].

In addition to direct differentiation, MSCs also exert profound effects through paracrine signaling. Paracrine factors are signaling molecules released by cells that have effects on nearby cells. MSCs secrete a variety of bioactive molecules, including cytokines, growth factors, and chemokines, which can modulate the local cellular environment and stimulate endogenous healing processes [11].

For instance, the secretion of vascular endothelial growth factor (VEGF) by MSCs plays a crucial role in the formation of new blood vessels—a process known as angiogenesis. Enhanced angiogenesis is vital for providing nutrients and oxygen to the healing bone and for the removal of waste products. Additionally, anti-inflammatory cytokines released by MSCs, such as interleukin-10 (IL-10), can inhibit pro-inflammatory responses and promote a more favorable environment for tissue repair [12].

Furthermore, stem cell-derived exosomes, which are nanosized extracellular vesicles, have gained attention for their role in mediating paracrine effects and facilitating communication between cells. These exosomes carry various bioactive molecules that can promote cell proliferation, enhance angiogenesis, and modulate immune responses, thereby further contributing to the efficacy of bone healing [12].

A critical aspect of effective bone healing involves the regulation of inflammation. An inappropriate inflammatory response can be detrimental to healing, leading to chronic inflammation and impaired tissue regeneration. MSCs possess innate immunomodulatory properties, enabling them to interact with various immune cells, such as T cells, B cells, and macrophages [13].

The ability of MSCs to secrete anti-inflammatory factors allows them to suppress the activity of pro-inflammatory T cells and promote the differentiation of regulatory T cells (Tregs), which further dampens the inflammatory response. This immune modulation is not only beneficial for reducing the inflammatory burden but also helps create a permissive environment for the proliferation and differentiation of stem cells and other reparative cells [14].

The microenvironment surrounding the injury site, often referred to as the niche, plays a crucial role in governing stem cell behavior. Factors such as mechanical stimuli, biochemical signals, and the overall composition of the extracellular matrix can significantly impact the fate of stem cells and their capacity for bone healing [14].

Mechanical loading is an important factor that influences stem cell differentiation. Dynamic mechanical forces experienced during movement can enhance the osteogenic differentiation of MSCs, promoting bone formation. Additionally, research has indicated that the stiffness and composition of the extracellular matrix can dictate the lineage commitment of MSCs, further highlighting the importance of the microenvironment in the bone healing process [15].

Types of Stem Cells Used in Bone Regeneration:

Bone regeneration is a field of regenerative medicine that has garnered considerable attention in recent years. The ability to heal and regenerate lost or damaged bone tissue is crucial for treating various conditions, including fractures, bone defects due to trauma, and degenerative diseases such as osteoporosis. Stem cells play a pivotal role in this process, owing to their inherent capacity for self-renewal and differentiation into various cell types. Among the various types of stem cells, several are particularly relevant to bone regeneration [16].

1. Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are among the most studied stem cells in the context of bone regeneration. These multipotent cells can differentiate into osteoblasts (bone-forming cells), chondrocytes (cartilage-forming cells), and adipocytes (fat-forming cells). MSCs can be isolated from various tissues, including bone marrow, adipose tissue, umbilical cord, and synovial fluid. Their accessibility and ability to be expanded in culture make them attractive candidates for regenerative therapies [16].

Mechanisms of Bone Regeneration: MSCs contribute to bone regeneration through several mechanisms. Primarily, they promote osteogenesis by differentiating into osteoblasts, which synthesize and secrete the components of the extracellular matrix essential for bone formation. Moreover, MSCs release various growth factors and cytokines that recruit other cells to the injury site and promote angiogenesis, which is vital for the healing process. These factors include vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-β), and bone morphogenetic proteins (BMPs) [17].

Clinical Applications: MSCs have been employed in various clinical applications, from treating non-union fractures to bone defects resulting from tumors or infections. Clinical trials have demonstrated promising results in enhancing the healing process, reducing pain, and improving function in patients receiving MSC-based therapies [18].

2. Hematopoietic Stem Cells (HSCs)

Hematopoietic stem cells (HSCs) are primarily known for their role in generating all blood cell types. They are primarily located in the bone marrow but can also be found in peripheral blood and umbilical cord blood. Although their primary function is hematopoiesis, recent studies have indicated that HSCs may also have potential in bone regeneration [18].

Mechanisms of Action: HSCs contribute to bone regeneration by participating in the hematopoietic niche and influencing the microenvironment of bone cells. They have been shown to secrete factors that support osteogenesis and inhibit osteoclastogenesis (the formation of bone-resorbing cells). Additionally, HSCs can differentiate into osteoblasts under specific conditions, although their osteogenic potential is less pronounced than that of MSCs [19].

Clinical Implications: Research exploring the role of HSCs in bone regeneration is still in its early stages, but their potential applications in combination therapies (e.g., with MSCs) are being investigated. The interaction between HSCs and MSCs within the bone marrow microenvironment could provide a synergistic effect that enhances bone healing [19].

3. Induced Pluripotent Stem Cells (iPSCs)

Induced pluripotent stem cells (iPSCs) are a remarkable innovation in stem cell research. They are generated by reprogramming somatic cells to a pluripotent state, allowing them to differentiate into any cell type in the body, including osteoblasts. The ability to derive iPSCs from easily accessible tissues, such as skin or blood, presents an opportunity to create patient-specific cell therapies [19].

Mechanisms of Osteogenesis: iPSCs can be induced to differentiate into osteoblasts through specific signaling pathways and culture conditions. When transplanted into bone defects or combined with biomaterials, they can support the formation of new bone tissue. The plasticity of iPSCs allows for extensive research into optimizing their differentiation and integration into existing tissues.

Clinical Perspectives: Research related to iPSCs in bone regeneration is primarily at the preclinical stage. However, their potential to generate autologous cells without the risk of immunological rejection offers exciting prospects for personalized medicine. The future of iPSC-based therapies in bone regeneration may revolutionize the treatment of complex bone injuries [20].

4. Dental Pulp Stem Cells (DPSCs)

Dental pulp stem cells (DPSCs) are a type of MSC found in the dental pulp of teeth. They possess self-renewal capabilities and the potential to differentiate into various cell types, including osteoblasts and neurogenic cells. Their relative ease of access due to dental procedures makes them a viable source of stem cells for therapeutic use [21].

Mechanisms of Action: DPSCs can contribute to bone regeneration by differentiating into osteoblasts and by secreting growth factors that promote tissue repair. Their unique properties also enable them to participate in the formation of mineralized tissue, providing a functional alternative to traditional bone grafts in certain dental and craniofacial applications [22].

Clinical Applications: DPSCs are being investigated for use in alveolar bone regeneration, particularly in dental implant procedures. Initial studies have shown that DPSCs can enhance bone healing and integration, providing a biocompatible source of cells for aiding bone regeneration in the craniofacial region [23].

5. Periosteum-Derived Stem Cells (PDSCs)

Periosteum-derived stem cells (PDSCs) are found in the periosteum, a dense connective tissue that covers the outer surface of bones. These cells have been identified as a source of MSCs with significant osteogenic potential. Given their anatomical location, PDSCs can play a critical role in bone repair and regeneration [24].

Mechanisms of Action: PDSCs can differentiate into osteoblasts and are particularly effective in bone regeneration. They contribute to periosteal bone healing and have been shown to stimulate angiogenesis in response to injury. The periosteal layer's natural involvement in bone homeostasis and wound healing makes PDSCs especially relevant to regenerative strategies.

Clinical Applications: There is growing interest in utilizing PDSCs for bone regeneration in orthopedic surgeries, such as the treatment of non-union fractures and bone defects. Their use may enhance the body's natural healing processes and improve surgical outcomes in patients requiring bone reconstruction [25].

Comparative Efficacy of Stem Cell Therapy Versus Traditional Treatments:

The rapid advancement of medical science has opened up new horizons in the treatment of various diseases, particularly those deemed chronic or degenerative in nature. Among the most promising developments is stem cell therapy, which has emerged as a potential alternative or complementary approach to traditional treatments. As the healthcare landscape evolves, comparing the efficacy of stem cell therapy with conventional medical interventions becomes both pressing and necessary.

Stem cell therapy involves the use of stem cells—undifferentiated cells capable of developing into different cell types—to treat or prevent diseases. These cells have the remarkable ability to self-renew and differentiate into specific cell lineages, which grants them substantial potential in regenerative medicine. Stem cell therapy can be categorized broadly into two types: **autologous**, where stem cells are sourced from the patient's own tissues, and **allogeneic**, where stem cells are harvested from a donor. Applications of stem cell therapy include, but are not limited to, conditions like spinal cord injuries, heart diseases, neurodegenerative disorders, and various types of cancer [26].

Traditional treatments encompass a wide array of therapeutic strategies, including pharmacotherapy, surgery, radiation therapy, and lifestyle interventions. These treatments have been the cornerstone of modern medicine, particularly for acute illnesses and severe injuries. Pharmacotherapy includes the use of drugs to alleviate symptoms or cure diseases, while surgical interventions can provide immediate relief from conditions like tumors or organ malformations. Although highly effective, traditional treatments often come with significant limitations such as side effects, recurrence of disease, and, in some cases, the inability to restore damaged tissues [27].

Efficacy: A Comparative Analysis

1. Curing versus Managing Diseases

Traditional treatments have historically focused on managing symptoms rather than curing underlying conditions. For instance, in cancer treatment, chemotherapy and radiation therapy aim to destruct malignant cells but also result in collateral damage to healthy tissues, leading to numerous side effects. On the other hand, stem cell therapy presents a paradigm shift by directly stimulating the body's own repair mechanisms. In conditions like heart disease, stem cells can potentially regenerate damaged cardiac tissue, offering long-term benefits compared to traditional measures, which primarily aim to control symptoms [28].

2. Rate of Recovery and Quality of Life

Patients undergoing traditional treatments often report prolonged recovery periods due to related side effects, such as fatigue, immunosuppression, and chronic pain. In comparison, stem cell therapy may offer a more expedited recovery process. Clinical studies indicate that patients treated with stem cells for conditions like osteoarthritis or neurological disorders often experience rapid improvements in mobility and functionality. A prime example can be observed in patients suffering from Multiple Sclerosis (MS), where stem cell therapy has shown promising results in halting disease progression and improving quality of life [29].

3. Personalized Medicine

A significant advantage of stem cell therapy lies in its ability to be tailored to an individual's needs, particularly when utilizing autologous stem cells. This personalization reduces the chances of rejection and adverse reactions, commonly seen in traditional treatments, particularly those involving donor tissues and organs. In contrast, traditional treatments often adopt a one-size-fits-all methodology, which may not account for the diverse therapeutic needs of individual patients [29].

4. Limitations and Risks

Despite its potential, stem cell therapy is not without its drawbacks. The technology is still in its infancy and is marred by ethical concerns, especially regarding embryonic stem cells. Furthermore, the long-term effects of such therapies remain largely unknown, raising questions about safety and effectiveness. Comparatively, traditional treatments are well-established, with extensive clinical guidelines and protocols refined through decades of research. The potential for adverse reactions, long-term complications, or treatment failures is significantly lower with traditional methods, underscoring the importance of cautious optimism when considering stem cell therapy [30].

Regulatory Landscape

The regulatory framework surrounding stem cell therapy is more complex and variable than that for traditional treatments. Clinical trials involving stem cells are often subject to rigorous scrutiny, partly due to safety concerns and the ethical implications of stem cell usage. In many regions, including the United States, stem cell products are regulated by the Food and Drug Administration (FDA), which has led to delays in bringing effective therapies to the public. Traditional treatments, however, have largely established regulatory pathways that ensure their safety and efficacy before reaching patients [30].

Clinical Applications and Case Studies of Stem Cell Therapy:

Stem cell therapy, a groundbreaking area in regenerative medicine, has gained significant traction over the past few decades. Stem cells, which possess the unique ability to differentiate into various cell types and self-renew, are a pivotal resource for treating a range of degenerative diseases, injuries, and conditions that were once deemed difficult or impossible to manage [30].

Overview of Stem Cell Types

Before examining clinical applications, it's essential to understand the types of stem cells used in therapy:

1. **Embryonic Stem Cells (ESCs)**: Derived from the inner cell mass of blastocysts, these cells can differentiate into virtually any cell type. Their pluripotent nature offers vast therapeutic possibilities but raises ethical concerns regarding their use [30].

2. **Adult Stem Cells (ASCs)**: Found in tissues like bone marrow or adipose tissue, ASCs are typically multipotent and more limited in their differentiation potential than ESCs. However, their use is often less controversial, making them a popular choice for clinical applications.

3. **Induced Pluripotent Stem Cells (iPSCs)**: These are adult somatic cells that have been genetically reprogrammed to exhibit pluripotent characteristics. iPSCs circumvent some ethical issues associated with ESCs, making them an

attractive option for research and potential therapies [30].

Clinical Applications

Stem cell therapy has shown promise across numerous medical fields, including hematology, orthopedics, cardiology, neurology, and more. Below, we explore several clinical applications along with relevant case studies that underscore their efficacy [31].

Hematologic Disorders

One of the most well-established applications of stem cell therapy is in the treatment of hematologic malignancies, such as leukemia. Hematopoietic stem cell transplantation (HSCT) is utilized to restore the blood and immune system in patients undergoing aggressive chemotherapy [31].

Case Study: In a notable case from the Fred Hutchinson Cancer Research Center, a 55-year-old patient diagnosed with acute myeloid leukemia underwent an allogeneic HSCT. Following a rigorous conditioning regimen, the patient received stem cells from a matched sibling donor. Post-transplant, the patient achieved complete remission, demonstrating the procedure's capability to reinvigorate immune defense and eradicate malignant cells. Long-term follow-up indicated sustained remission and an improved quality of life, highlighting HSCT's potential as a curative approach for blood cancers [31].

Orthopedic Applications

In orthopedics, stem cell therapy has emerged as a viable treatment for conditions such as osteoarthritis, cartilage injuries, and non-union fractures. The potential to regenerate damaged tissues makes stem cells an appealing option [32].

Case Study: A multicenter clinical trial assessed the use of mesenchymal stem cells (MSCs) derived from bone marrow to treat knee osteoarthritis. In this study, participants received autologous MSC injections directly into the affected joint. Results at 12 months showed significant improvements in pain scores and joint function compared to baseline measurements. Imaging studies revealed enhanced cartilage regeneration in treated areas, suggesting that stem cell therapy could alter the disease trajectory and restore functional mobility [32].

Cardiovascular Diseases

The application of stem cell therapy in cardiology focuses on repairing heart tissue post-myocardial infarction and treating chronic heart failure. The ability of stem cells to differentiate into cardiomyocytes offers a potent strategy for cardiac regeneration [33].

Case Study: In a pioneering trial published in the Journal of the American College of Cardiology, scientists explored the effects of injecting cardiac-derived stem cells into patients with ischemic heart disease. The study involved 50 patients who received injections during coronary artery bypass surgery. Follow-up echocardiograms indicated improvements in left ventricular ejection fraction and reduced scar size compared to standard postoperative care. Patients reported enhanced exercise capacity and quality of life metrics, illustrating stem cells' potential to restore heart function [33].

Neurological Disorders

Neurological diseases such as Parkinson's disease, multiple sclerosis, and spinal cord injuries pose significant challenges. Stem cell therapy presents innovative avenues for cell replacement and neuroprotection [34].

Case Study: One seminal case involved a 34-year-old woman with severe multiple sclerosis who participated in an early-phase clinical trial using autologous iPSC-derived neural stem cells. Following preconditioning chemotherapy, the trial participants received the infusion of engineered iPSCs. Remarkably, after a year, the patient experienced a reduction in neurological symptoms, along with improvements in mobility and cognitive function. This landmark case suggests that stem cells may not only halt disease progression but also encourage neural regeneration [34].

Challenges and Considerations

While the clinical applications of stem cell therapy yield promising results, several challenges persist. Issues such as ethical dilemmas regarding ESCs, the potential risk of tumorigenesis with iPSCs, and the need for standardized protocols pose significant barriers. Additionally, there is a necessitated focus on long-term safety and efficacy profiles, particularly in emerging fields such as gene editing and personalized medicine.

Moreover, the diversity in patient responses to stem cell treatments compels researchers and clinicians to understand the underlying biological mechanisms driving these therapies. Factors such as age, disease stage, and specific stem cell characteristics can significantly influence outcomes, necessitating tailored approaches to treatment [34].

Challenges and Limitations in Stem Cell-Based Bone Regeneration:

Stem cell therapy has emerged as a landmark advancement in regenerative medicine, particularly in the context of bone regeneration. The use of stem cells for repairing bone tissue promises a revolutionary approach to treating skeletal injuries, defects, and degenerative diseases. However, despite the considerable enthusiasm surrounding this modality, a myriad of challenges and limitations persists. These hurdles encompass scientific, technical, practical, and ethical aspects that must be addressed to fully harness the potential of stem cell-based bone regeneration [35].

1. Biological Challenges

One of the primary challenges in stem cell-based bone regeneration lies in the complexity of bone biology and the multifaceted nature of healing processes. Bone regeneration is not merely a matter of filling defects with appropriate cells; it also necessitates a conducive environment that supports the cellular activity, structure formation, and integration with surrounding tissues. Specifically, stem cells must not only differentiate into osteoblasts—which are essential for bone formation—but must also integrate into existing bone matrices, interact with vascular systems, and respond appropriately to biomechanical stresss [36].

Additionally, the origin of the stem cells influences their behavior and effectiveness. Various types of stem cells have been studied, including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs). Each source comes with its inherent advantages and limitations concerning differentiation capacity, immunogenicity, and ethical considerations. For instance, while ESCs can differentiate into virtually any cell type, their sourcing poses significant ethical dilemmas that can hinder their application in clinical settings. Conversely, MSCs, while more easily obtainable from adult tissues such as bone marrow or adipose tissue, display limited proliferation potential and may suffer from declining regenerative capacity with age [37].

2. Technical Limitations

The technicalities surrounding stem cell isolation, expansion, and differentiation represent another significant barrier. The processes for obtaining and expanding stem cells in vitro can be resource-intensive, costly, and time-consuming. Ensuring that stem cells maintain their undifferentiated state during culture, while still promoting directed differentiation toward osteogenic pathways, requires precise control over culture conditions, including the optimum combination of growth factors, matrix materials, and mechanical stimuli [38].

In addition, there's growing evidence suggesting the importance of extracellular matrices (ECMs) in guiding stem cell differentiation. The design and synthesis of biomimetic scaffolds that can adequately support stem cell growth and differentiation while providing structural integrity during healing present formidable engineering challenges. Indeed, scaffolds must not only enable cell adhesion and proliferation but also facilitate the transport of nutrients and metabolic waste and eventually resorb in a timely manner to allow for new bone tissue integration [38].

3. Immunological Issues

The immunogenicity of stem cells presents another critical challenge in the context of bone regeneration. When transplanted into a different host, stem cells may evoke immune reactions, which can lead to inflammation or rejection. This issue is particularly pertinent when using allogeneic stem cells, derived from donors. Automating stem cell technologies, including gene-editing tools like CRISPR, promises to address some of these immunogenicity challenges. However, its application in human subjects is still in nascent stages and currently elicits concerns about unforeseen genetic consequences or ethical considerations surrounding genetic modifications [39].

Furthermore, the interplay between stem cells and the immune system remains a complex and poorly understood area of research. The immune milieu not only influences the fate of grafted stem cells but also the healing process itself. Adequate strategies to modulate immune responses without compromising bone healing efficacy are urgently needed and represent a significant gap in current understanding [39].

4. Clinical Translation and Regulatory Hurdles

As with any emerging therapeutic area, translating stem cell-based approaches from laboratory settings to clinical applications poses substantial obstacles. The pathways for approval of new therapeutic techniques can be lengthy and complex, requiring extensive preclinical studies and clinical trials to establish the safety and efficacy of stem cell interventions. This lengthy regulatory process often results in delayed access to potentially transformative therapies for patients suffering from bone-related disorders [40].

Moreover, the translation from bench to bedside may also be hampered by a lack of standardized protocols for stem cell handling, treatment application, and patient monitoring. Different methodologies used across clinical studies can render results difficult to interpret and may contribute to variability in outcomes, challenging the establishment of best practices for clinical use [40].

5. Ethical and Societal Considerations

Apart from technical and biological issues, ethical concerns regarding the use of stem cells remain at the forefront of the discourse surrounding regenerative medicine. For instance, debates regarding the moral implications of using embryonic stem cells continue to spark controversy, leading to restrictions in certain countries. Such ethical quandaries complicate not only the progression of scientific research but also public acceptance of stem cell-based therapies.

Furthermore, access to advanced therapies—including those based on stem cells—raises issues of equity and social justice. The high costs and sophisticated infrastructure requirements for stem cell applications may limit availability to certain populations, exacerbating health disparities [41].

Future Directions in Stem Cell Research for Bone Healing:

The field of regenerative medicine has witnessed significant advancements over the past few decades, particularly in the realm of stem cell research. With capabilities to differentiate into various specialized cell types, stem cells hold immense promise for therapeutic applications, especially in bone healing and regeneration. As injuries related to the skeletal system are prevalent and often challenging to treat, the exploration of stem cell therapies for enhanced bone healing has become a focal point for researchers and clinicians alike [42].

Stem cells are undifferentiated cells with the unique ability to self-renew and differentiate into various specialized cell types. There are two main categories of stem cells: embryonic stem cells (ESCs) and adult stem cells (ASCs), also known as somatic stem cells. ESCs are derived from early-stage embryos, while ASCs are found in various tissues throughout the body, including bone marrow, adipose tissue, and dental pulp. Within ASCs, mesenchymal stem cells (MSCs) are particularly relevant for bone healing as they can differentiate into osteoblasts, chondrocytes, and adipocytes, making them pivotal in the repair and regeneration of bone tissue]42].

Current Landscape of Stem Cell Research in Bone Healing

Traditionally, the treatment of bone defects and injuries has relied on methods such as autografts, allografts, and synthetic bone grafts. However, these approaches often come with complications, including donor site morbidity, immune rejection, and limited availability of suitable grafting material. The utilization of stem cells in bone healing offers a paradigm shift that aims to enhance natural repair mechanisms and create new bone tissue. Currently, approaches incorporating MSCs have shown promise in preclinical and clinical studies, offering a glimpse into the potential benefits of stem cell therapies in enhancing bone healing.

One of the promising areas in current stem cell research involves the use of various scaffolds or carriers that can support and guide the differentiation of stem cells into bone-forming cells. These scaffolds can be biocompatible, biodegradable materials that mimic the extracellular matrix and provide the necessary support for cells during the healing process. Incorporating growth factors, such as bone morphogenetic proteins (BMPs), within these scaffolds has shown to synergize with stem cell therapies, leading to improved bone regeneration outcomes [43].

Future Directions

1. **Engineering Advanced Biomaterials:** One of the critical areas for future developments in stem cell therapy for bone healing is the engineering of advanced biomaterials that can enhance cell delivery and function. Researchers are exploring the use of 3D printing technology and bioactive glasses to create custom scaffolds tailored to the specific requirements of a given injury or defect. These smart biomaterials can be incorporated with growth factors and signaling molecules that promote stem cell survival, proliferation, and differentiation [44].

2. **Utilization of Induced Pluripotent Stem Cells (iPSCs):** The emergence of induced pluripotent stem cell (iPSC) technology has expanded the horizon for stem cell research. iPSCs are adult cells that have been genetically reprogrammed to an embryonic stem cell-like state, allowing them to differentiate into a wide variety of cell types, including osteoblasts. Utilizing iPSCs in bone healing research could mitigate ethical concerns associated with ESCs and provide a patient-specific approach to treatment, potentially reducing the risk of immune rejection [44].

3. **Combination Therapies:** The integration of stem cell therapy with other regenerative medicine strategies can enhance efficacy for bone healing. Future research may focus on combination therapies that integrate stem cells with gene therapy, where genetic modifications can enhance the regenerative capabilities of the cells. Additionally, combining stem cell treatments with physical therapies such as electrical stimulation or low-intensity pulsed ultrasound could further promote bone healing through synergistic effects [45].

4. **Exploring the Role of the Microenvironment:** A growing body of research highlights the importance of the cellular microenvironment in stem cell function and differentiation. Future studies may focus on understanding how varying conditions in the local microenvironment can be manipulated to favor the osteogenic differentiation of stem cells. Factors such as mechanical loading, hypoxia, and the presence of specific cytokines will all be critical areas of investigation to optimize stem cell therapy for bone healing [46].

5. **Clinical Translation and Standardization:** Although preclinical studies have shown promising results, translating stem cell therapies into routine clinical practice poses significant challenges. Establishing standardized protocols for stem cell isolation, expansion, and differentiation is essential for ensuring consistent therapeutic outcomes. Regulatory pathways must be addressed to facilitate the approval of stem cell-based therapies, allowing them to reach patients more efficiently [47].

6. **Understanding Long-Term Outcomes and Safety:** Longitudinal studies to evaluate the long-term efficacy and safety of stem cell treatments for bone healing are crucial. There is a need for comprehensive investigations that assess bone quality, mechanical strength, and the potential for tumorigenesis or adverse effects over extended periods. Ensuring patient safety and solidifying the scientific foundation of these therapies will be crucial for the broader acceptance of stem cell interventions [48].

Ethical Considerations and Regulatory Frameworks in Stem Cell Therapy:

Stem cell therapy has emerged as a promising avenue for treating various medical conditions, with bone healing being one of the most intriguing applications. The ability to regenerate bone tissue using stem cells has the potential to revolutionize orthopedic medicine, particularly for conditions such as fractures, osteoporosis, and non-union bone injuries. However, pioneers in this field face significant ethical concerns and regulatory complexities that must be navigated to ensure patient safety and equitable access to these advanced therapies [49].

The Science of Stem Cell Therapy in Bone Healing

Stem cells possess unique capabilities that allow them to differentiate into various cell types, including osteoblasts, which are critical for bone formation. In the context of bone healing, stem cells can be sourced from different origins, including:

1. **Embryonic Stem Cells (ESCs)**: Derived from early-stage embryos, these cells have the potential to differentiate into any cell type, offering a high degree of plasticity. However, ethical

controversies surrounding the use of human embryos have limited their application [50].

2. **Adult Stem Cells (ASCs)**: These are found in tissues like bone marrow and adipose tissue. ASCs exhibit a more limited differentiation capacity compared to ESCs but have been widely studied for their roles in regenerative medicine due to their ethical acceptability and easier accessibility [51].

3. **Induced Pluripotent Stem Cells (iPSCs)**: iPSCs are engineered from adult cells, granting them pluripotent capabilities similar to ESCs. This innovation opens potential avenues for personalized therapies but also raises questions regarding the methods of generation and long-term implications [52].

The application of these stem cells in bone healing includes the development of scaffolds that can support bone regeneration, the injection of stem cells into the site of injury, and the use of bioactive substances to enhance the efficacy of the stem cell therapy [52].

Ethical Considerations

1. **Use of Embryonic Stem Cells**: The primary ethical dilemma surrounding stem cell therapy involves embryonic stem cells. The extraction of these cells necessitates the destruction of an embryo, raising profound moral questions regarding the status of human life. Different cultures and belief systems hold varying views on when life begins, which complicates the consensus on this issue. Ethical frameworks must consider the balance between potential medical benefits and the moral considerations of creating and discarding human embryos [53].

2. **Informed Consent and Autonomy**: The principle of informed consent is vital in any medical intervention, particularly in experimental therapies like stem cell treatments. Patients must be fully apprised of the potential risks, benefits, and uncertainties associated with stem cell therapy. There is a risk that patients may not understand the experimental nature of the procedure, which could lead to unrealistic expectations and a lack of informed decision-making [54].

3. **Equity and Access**: Concerns about equity arise in the context of emerging therapies, including stem cell treatments. With the high costs associated with advanced therapies, access may be limited to affluent individuals or those with adequate insurance coverage. Ethical considerations should address how to ensure equitable access to these potentially life-changing treatments for all segments of the population [55].

4. **Long-Term Consequences**: The long-term effects of stem cell therapy are still not fully understood. There is potential for complications such as tumorigenesis, where the stem cells may develop into cancerous cells. Ethical research practices require rigorous long-term follow-up studies to assess the safety and efficacy of these treatments, ensuring that patients are not exposed to undue risk [56].

5. **Commercialization and Exploitation**: The commercialization of stem cell therapies presents another ethical challenge. As the demand for these therapies grows, the risk of unproven and unregulated treatments entering the market also increases. Patients may find themselves vulnerable to exploitation by practitioners promoting unverified stem cell therapies, which raises significant ethical concerns regarding patient safety and integrity in medical practice [57].

Regulatory Frameworks

The regulatory landscape surrounding stem cell therapy is complex and varies by country. Effective regulation is essential to protect patients and ensure the ethical application of these therapies.

1. **Overview of Regulatory Bodies**: In the United States, the Food and Drug Administration (FDA) plays a critical role in overseeing stem cell therapies. The FDA categorizes stem cell treatments based on their intended use and regulates them accordingly. Cellular therapies with significant risk must undergo preclinical and clinical trials, while less invasive treatments may be classified as minimal manipulation and may face different levels of scrutiny [58].

2. **International Perspectives**: Regulatory frameworks differ widely across countries. In Europe, for instance, the European Medicines Agency (EMA) regulates advanced therapy medicinal products (ATMPs), including stem cell therapies. In countries like Australia, the Therapeutic Goods Administration (TGA) has stringent guidelines for the use of stem cells,

whereas other regions may have more lenient regulations or lack comprehensive oversight [59].

3. **Ethical Guidelines and Best Practices**: In addition to legal regulations, ethical guidelines developed by professional organizations, such as the International Society for Stem Cell Research (ISSCR), provide a framework for researchers and practitioners. These guidelines promote ethical research practices, emphasizing rigorous scientific methods, informed consent, transparency, and patient welfare [60].

4. **Collaboration Across Disciplines**: The evolving nature of stem cell therapy necessitates collaboration among scientists, ethicists, regulatory agencies, and patient advocacy groups. Interdisciplinary dialogues can promote a holistic understanding of the implications of stem cell research and therapy, ensuring that ethical considerations are integrated into the development and regulation of these treatments [61].

Conclusion:

Stem cell therapy presents a significant advancement in the field of bone regeneration, offering transformative potential for treating complex bone defects and enhancing healing processes. The ability of stem cells to differentiate into osteoblasts and secrete bioactive factors plays a crucial role in promoting bone tissue regeneration, providing a promising alternative to traditional surgical interventions. Clinical evidence supports the efficacy of stem cell therapies, which show improved healing outcomes and functional recovery in various orthopedic conditions.

However, while the results are promising, challenges remain, including variability in patient outcomes, optimal cell sourcing and delivery methods, and the need for standardized protocols. Ongoing research is crucial for addressing these challenges, refining methodologies, and expanding the clinical applications of stem cell therapy in bone regeneration. As we continue to explore the potential of this innovative approach, it is essential to balance scientific advancement with ethical considerations and regulatory compliance to ensure patient safety and treatment efficacy. Overall, stem cell therapy holds great promise for revolutionizing the management of bone injuries and defects, paving the way for future breakthroughs in regenerative medicine.

References:

1. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103:1204–1219. doi: 10.1161/CIRCRESAHA.108.176826.
2. Aykan A, Ozturk S, Sahin I, Gurses S, Ural AU, Oren NC, Isik S. Biomechanical analysis of the effect of mesenchymal stem cells on mandibular distraction osteogenesis. J Craniofac Surg. 2013;24:e169–175. doi: 10.1097/SCS.0b013e31827c8706.
3. Yew TL, Huang TF, Ma HL, Hsu YT, Tsai CC, Chiang CC, Chen WM, Hung SC. Scale-up of MSC under hypoxic conditions for allogeneic transplantation and enhancing bony regeneration in a rabbit calvarial defect model. J Orthop Res. 2012;30:1213–1220. doi: 10.1002/jor.22070.
4. Li H, Dai K, Tang T, Zhang X, Yan M, Lou J. Bone regeneration by implantation of adipose-derived stromal cells expressing BMP-2. Biochem Biophys Res Commun. 2007;356:836–842. doi: 10.1016/j.bbrc.2007.02.165.
5. Zhou H, Xiao C, Wang Y, Bi X, Ge S, Fan X. In vivo efficacy of bone marrow stromal cells coated with beta-tricalcium phosphate for the reconstruction of orbital defects in canines. Invest Ophthalmol Vis Sci. 2011;52:1735–1741. doi: 10.1167/iovs.10-5988.
6. Cui L, Liu B, Liu G, Zhang W, Cen L, Sun J, Yin S, Liu W, Cao Y. Repair of cranial bone defects with adipose derived stem cells and coral scaffold in a canine model. Biomaterials. 2007;28:5477–5486. doi: 10.1016/j.biomaterials.2007.08.042.
7. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ. 2001;323:42–46. doi: 10.1136/bmj.323.7303.42.
8. Ren ML, Peng W, Yang ZL, Sun XJ, Zhang SC, Wang ZG, Zhang B. Allogeneic adipose-derived stem cells with low immunogenicity constructing tissue-engineered bone for repairing bone defects in pigs. Cell Transplant. 2012;21:2711–2721. doi: 10.3727/096368912X654966.
9. Yan Z, Hang D, Guo C, Chen Z. Fate of mesenchymal stem cells transplanted to

osteonecrosis of femoral head. J Orthop Res. 2009;27:442–446. doi: 10.1002/jor.20759.

10. Lai RC, Arslan F, Lee MM, Sze NS, Choo A, Chen TS. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;4:214–222. doi: 10.1016/j.scr.2009.12.003.

11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. doi: 10.1136/bmj.327.7414.557.

12. Wang L, Fan H, Zhang ZY, Lou AJ, Pei GX, Jiang S, Mu TW, Qin JJ, Chen SY, Jin D. Osteogenesis and angiogenesis of tissue-engineered bone constructed by prevascularized β-tricalcium phosphate scaffold and mesenchymal stem cells. Biomaterials. 2010;31:9452–9461. doi: 10.1016/j.biomaterials.2010.08.036.

13. Vrijsen KR, Sluijter JP, Schuchardt MW, van Balkom BW, Noort WA, Chamuleau SA, Doevendans PA. Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial cells. J Cell Mol Med. 2010;14:1064–1070. doi: 10.1111/j.1582-4934.2010.01081.x.

14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188. doi: 10.1016/0197-2456(86)90046-2.

15. Green S, Higgins JP, Alderson P, Clarke M, Mulrow CD, Oxman AD. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Chichester, UK: John Wiley & Sons, Ltd; 2008.

16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634. doi: 10.1136/bmj.315.7109.629.

17. Caplan A.I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 2007;213:341–347. doi: 10.1002/jcp.21200.

18. Sakkas A., Wilde F., Heufelder M., Winter K., Schramm A. Autogenous bone grafts in oral implantology—is it still a “gold standard”? A consecutive review of 279 patients with 456 clinical procedures. Int J Implant Dent. 2017;3:23. doi: 10.1186/s40729-017-0084-4.

19. Pjetursson B.E., Karoussis I., Bürgin W., Brägger U., Lang N.P. Patients' satisfaction following implant therapy: a 10-year prospective cohort study. Clin Oral Implants Res. 2005;16:185–193. doi: 10.1111/j.1600-0501.2004.01094.x.

20. Hargreaves K.M., Diogenes A., Teixeira F.B. Treatment options: biological basis of regenerative endodontic procedures. J Endod. 2013;39:S30–S43. doi: 10.1016/j.joen.2012.11.025.

21. Mertens C., Meyer-Bäumer A., Kappel H., Hoffmann J., Steveling H.G. Use of 8-mm and 9-mm implants in atrophic alveolar ridges: 10-year results. Int J Oral Maxillofac Implants. 2012;27:1501–1508.

22. Östman P.O., Hellman M., Sennerby L. Ten Years Later: results from a prospective single-centre clinical study on 121 oxidized (TiUniteTM) Brånemark implants in 46 patients. Clin Implant Dent Relat Res. 2012;14:852–860. doi: 10.1111/j.1708-8208.2012.00453.x.

23. Pejcic A., Kojovic D., Mirkovic D., Minic I. Stem cells for periodontal regeneration. Balkan J Med Genet. 2013;16:7–12. doi: 10.2478/bjmg-2013-0012.

24. Amini A.R., Laurencin C.T., Nukavarapu S.P. Bone tissue engineering: recent advances and challenges. Crit Rev Biomed Eng. 2012;40:363–408. doi: 10.1615/critrevbiomedeng.v40.i5.10.

25. Nishimura M., Takase K., Suehiro F., Murata H. Candidates cell sources to regenerate alveolar bone from oral tissue. Int J Dentistr. 2012;2012:1–5. doi: 10.1155/2012/857192.

26. Esposito M., Grusovin M.G., Kwan S., Worthington H.V., Coulthard P. Interventions for replacing missing teeth: bone augmentation techniques for dental implant treatment. Cochrane Database Syst Rev. 2008;3:1–69. doi: 10.1002/14651858.CD003607.pub3.

27. Macchiarini P., Jungebluth P., Go T. Clinical transplantation of a tissue-engineered airway. Lancet. 2008;372:2023–2030. doi: 10.1016/S0140-6736(08)61598-6.

28. Shanti R.M., Li W.J., Nesti L.J., Wang X., Tuan R.S. Adult mesenchymal stem cells: biological properties, characteristics, and applications in maxillofacial surgery. J Oral Maxillofac Surg. 2007;65:1640–1647. doi: 10.1016/j.joms.2007.04.008.

29. Mao J.J., Giannobile W.V., Helms J.A. Craniofacial tissue engineering by stem cells. J Dent Res. 2006;85:966–979. doi: 10.1177/154405910608501101.

30. Greenberg J.A., Wiltz M.J., Kraut R.A. Augmentation of the anterior maxilla with intraoral onlay grafts for implant placement. Implant Dent. 2012;21:21–24. doi: 10.1097/ID.0b013e3182435ffd.

31. Rayment E.A., Williams D.J. Concise review: mind the gap: challenges in characterizing and quantifying cell- and tissue-based therapies for clinical translation. Stem Cell. 2010;28:996–1004. doi: 10.1002/stem.416.

32. Hynes K., Menicanin D., Gronthos S., Bartold P.M. Clinical utility of stem cells for periodontal regeneration. Periodontol. 2000;59:203-27. doi: 10.1111/j.1600-0757.2012.00443.x.

33. Sen RK, Tripathy SK, Aggarwal S, Marwaha N, Sharma RR, Khandelwal N. Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomized control study. J Arthroplasty. 2012;27:679–686.

34. Peng J, Wen C, Wang A, Wang Y, Xu W, Zhao B, Zhang L, Lu S, Qin L, Guo Q, Dong L, Tian J. Micro-CT-based bone ceramic scaffolding and its performance after seeding with mesenchymal stem cells for repair of load-bearing bone defect in canine femoral head. J Biomed Mater Res B Appl Biomater. 2011;96:316–325.

35. Mierisch CM, Wilson HA, Turner MA, Milbrandt TA, Berthoux L, Hammarskjöld ML, Rekosh D, Balian G, Diduch DR. Chondrocyte transplantation into articular cartilage defects with use of calcium alginate: the fate of the cells. J Bone Joint Surg Am. 2003;85-A:1757–1767.

36. Chang YJ, Shih DT, Tseng CP, Hsieh TB, Lee DC, Hwang SM. Disparate mesenchyme-lineage tendencies in mesenchymal stem cells from human bone marrow and umbilical cord blood. Stem Cells. 2006;24:679–685.

37. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7:211–228.

38. Jang BJ, Byeon YE, Lim JH, Ryu HH, Kim WH, Koyama Y, Kikuchi M, Kang KS, Kweon OK. Implantation of canine umbilical cord blood-derived mesenchymal stem cells mixed with beta-tricalcium phosphate enhances osteogenesis in bone defect model dogs. J Vet Sci. 2008;9:387–393.

39. Liao HT, Chen CT, Chen CH, Chen JP, Tsai JC. Combination of guided osteogenesis with autologous platelet-rich fibrin glue and mesenchymal stem cell for mandibular reconstruction. J Trauma. 2011;70:228–237.

40. Ai J, Ebrahimi S, Khoshzaban A, Jafarzadeh Kashi TS, Mehrabani D. Tissue engineering using human mineralized bone xenograft and bone marrow mesenchymal stem cells allograft in healing of tibial fracture of experimental rabbit model. Iran Red Crescent Med J. 2012;14:96–103.

41. Niemeyer P, Schönberger TS, Hahn J, Kasten P, Fellenberg J, Suedkamp N, Mehlhorn AT, Milz S, Pearce S. Xenogenic transplantation of human mesenchymal stem cells in a critical size defect of the sheep tibia for bone regeneration. Tissue Eng Part A. 2010;16:33–43.

42. Biondi-Zoccai GG, Abbate A, Parisi Q, Agostoni P, Burzotta F, Sandroni C, Zardini P, Biasucci LM. Is vasopressin superior to adrenaline or placebo in the management of cardiac arrest? A meta-analysis. Resuscitation. 2003;59:221–224.

43. Pavesio A, Abatangelo G, Borrione A, Brocchetta D, Hollander AP, Kon E, Torasso F, Zanasi S, Marcacci M. Hyaluronan-based scaffolds (Hyalograft C) in the treatment of knee cartilage defects: preliminary clinical findings. Novartis Found Symp. 2003;249:203–217.

44. Dragoo JL, Choi JY, Lieberman JR, Huang J, Zuk PA, Zhang J, Hedrick MH, Benhaim P. Bone induction by BMP-2 transduced stem cells

derived from human fat. J Orthop. 2003;21:622–629.

45. Verfaillie CM, Schwartz R, Reyes M, Jiang Y. Unexpected potential of adult stem cells. Ann N Y Acad Sci. 2003;996:231–234.
46. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:641–650.
47. Yan X.Z., Yang F., Jansen J.A., de Vries R.B., van den Beucken J.J. Cell-based approaches in periodontal regeneration: a systematic review and meta-analysis of periodontal defect models in animal experimental work. Tissue Eng B Rev. 2015;21:411–426.
48. Gjerde C., Mustafa K., Hellem S. Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial. Stem Cell Res Ther. 2018;9:213.
49. Wildburger A., Payer M., Jakse N., Strunk D., Etchard-Liechtenstein N., Sauerbier S. Impact of autogenous concentrated bone marrow aspirate on bone regeneration after sinus floor augmentation with a bovine bone substitute—a split-mouth pilot study. Clin Oral Implants Res. 2014;25:1175–1181.
50. Tassi S.A., Sergio N.Z., Misawa M.Y.O., Villar C.C. Efficacy of stem cells on periodontal regeneration: systematic review of pre-clinical studies. J Periodontal Res. 2017;52:793–812.
51. Caplan A.I. Review: mesenchymal stem cells: cell-based reconstructive therapy in orthopedics. Tissue Eng. 2005;11:1198-211.
52. Slot W., Raghoebar G.M., Vissink A., Huddleston Slater J.J., Meijer H.J. A systematic review of implant-supported maxillary overdentures after a mean observation period of at least 1 year. J Clin Periodontol. 2010;37:98-110.
53. Schimming R., Schmelzeisen R. Tissue-engineered bone for maxillary sinus augmentation. J Oral Maxillofac Surg. 2004;62:724–729.
54. Pieri F., Lucarelli E., Corinaldesi G. Mesenchymal stem cells and platelet-rich plasma enhance bone formation in sinus grafting: a histomorphometric study in minipigs. J Clin Periodontol. 2008;35:539–546.
55. Voss P., Sauerbier S., Wiedmann-Al-Ahmad M. Bone regeneration in sinus lifts: comparing tissue-engineered bone and iliac bone. Br J Oral Maxillofac Surg. 2010;48:121–126.
56. Gutwald R., Haberstroh J., Kuschnierz J. Mesenchymal stem cells and inorganic bovine bone mineral in sinus augmentation: comparison with augmentation by autologous bone in adult sheep. Br J Oral Maxillofac Surg. 2010;48:285–290.
57. Yamada Y., Nakamura S., Ito K. Injectable tissue-engineered bone using autogenous bone marrow-derived stromal cells for maxillary sinus augmentation: clinical application report from a 2-6 year follow-up. Tissue Eng. 2008;14:1699–1707.
58. Rickert D., Sauerbier S., Nagursky H., Menne D., Vissink A., Raghoebar G.M. Maxillary sinus floor elevation with bovine bone mineral combined with either autogenous bone or autogenous stem cells: a prospective randomized clinical trial. Clin Oral Implants Res. 2011;22:251–258.
59. Kaigler D., Avila-Ortiz G., Travan S. Bone engineering of maxillary sinus bone deficiencies using enriched CD90+ stem cell therapy: a randomized clinical trial. J Bone Miner Res. 2015;30:1206–1216.
60. Rickert D., Vissink A., Slot W.J., Sauerbier S., Meijer H.J., Raghoebar G.M. Maxillary sinus floor elevation surgery with BioOss® mixed with a bone marrow concentrate or autogenous bone: test of principle on implant survival and clinical performance. Int J Oral Maxillofac Surg. 2014;43:243–247.
61. Misawa M.Y.O., Huynh-Ba G., Villar G.M., Villar C.C. Efficacy of stem cells on the healing of peri-implant defects: systematic review of preclinical studies. Clin Exp Dent Res. 2016;2:18-34.